ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 150 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $137,827 | -88.3% | 12,339 | -77.6% | 0.00% | – |
Q2 2023 | $1,178,862 | -48.0% | 55,087 | -1.7% | 0.00% | -100.0% |
Q1 2023 | $2,266,339 | -13.6% | 56,042 | -0.6% | 0.00% | 0.0% |
Q4 2022 | $2,622,892 | -8.0% | 56,382 | +2.6% | 0.00% | 0.0% |
Q3 2022 | $2,851,000 | +9.2% | 54,978 | -0.5% | 0.00% | 0.0% |
Q2 2022 | $2,612,000 | -33.5% | 55,251 | +0.1% | 0.00% | 0.0% |
Q1 2022 | $3,928,000 | -4.8% | 55,182 | +0.0% | 0.00% | 0.0% |
Q4 2021 | $4,125,000 | +44.2% | 55,166 | +9.6% | 0.00% | 0.0% |
Q3 2021 | $2,860,000 | +39.5% | 50,354 | +8.1% | 0.00% | 0.0% |
Q2 2021 | $2,050,000 | -29.3% | 46,591 | -20.7% | 0.00% | 0.0% |
Q1 2021 | $2,899,000 | +18.9% | 58,769 | +1.4% | 0.00% | 0.0% |
Q4 2020 | $2,439,000 | -7.9% | 57,940 | +0.2% | 0.00% | 0.0% |
Q3 2020 | $2,648,000 | -1.4% | 57,828 | +8.1% | 0.00% | 0.0% |
Q2 2020 | $2,685,000 | +1.8% | 53,481 | +4.3% | 0.00% | -50.0% |
Q1 2020 | $2,637,000 | -8.7% | 51,270 | +9.7% | 0.00% | +100.0% |
Q4 2019 | $2,887,000 | +9.9% | 46,745 | +6.9% | 0.00% | 0.0% |
Q3 2019 | $2,627,000 | -25.1% | 43,726 | +5.2% | 0.00% | -50.0% |
Q2 2019 | $3,506,000 | -10.9% | 41,549 | +0.9% | 0.00% | 0.0% |
Q1 2019 | $3,935,000 | +48.9% | 41,194 | +10.1% | 0.00% | 0.0% |
Q4 2018 | $2,642,000 | -18.3% | 37,426 | +0.0% | 0.00% | 0.0% |
Q3 2018 | $3,232,000 | -2.8% | 37,415 | +29.2% | 0.00% | -33.3% |
Q2 2018 | $3,324,000 | +52.8% | 28,950 | +7.0% | 0.00% | +50.0% |
Q1 2018 | $2,175,000 | +41.1% | 27,064 | +3.1% | 0.00% | +100.0% |
Q4 2017 | $1,542,000 | +26.6% | 26,259 | +0.8% | 0.00% | 0.0% |
Q3 2017 | $1,218,000 | +34.4% | 26,042 | +3.5% | 0.00% | 0.0% |
Q2 2017 | $906,000 | +27.4% | 25,166 | +9.0% | 0.00% | 0.0% |
Q1 2017 | $711,000 | -10.6% | 23,086 | -2.7% | 0.00% | 0.0% |
Q4 2016 | $795,000 | +140.9% | 23,719 | +91.1% | 0.00% | – |
Q3 2016 | $330,000 | +450.0% | 12,409 | +348.6% | 0.00% | – |
Q2 2016 | $60,000 | -26.8% | 2,766 | 0.0% | 0.00% | – |
Q1 2016 | $82,000 | +24.2% | 2,766 | +39.0% | 0.00% | – |
Q4 2015 | $66,000 | -4.3% | 1,990 | 0.0% | 0.00% | – |
Q3 2015 | $69,000 | -21.6% | 1,990 | 0.0% | 0.00% | – |
Q2 2015 | $88,000 | +41.9% | 1,990 | 0.0% | 0.00% | – |
Q1 2015 | $62,000 | -38.6% | 1,990 | 0.0% | 0.00% | – |
Q4 2014 | $101,000 | +27.8% | 1,990 | 0.0% | 0.00% | – |
Q3 2014 | $79,000 | – | 1,990 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |